Keros Therapeutics (NASDAQ:KROS) Upgraded to “Hold” at Zacks Research

Keros Therapeutics (NASDAQ:KROS) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

A number of other analysts also recently weighed in on KROS. Leerink Partners decreased their price target on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Keros Therapeutics in a research report on Wednesday, August 12th. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Keros Therapeutics in a report on Tuesday, August 4th. Wall Street Zen upgraded shares of Keros Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, August 24th. Finally, Wells Fargo & Company lowered their price target on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 4th. Four equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $20.50.

Keros Therapeutics Stock Down 1.8%

Shares of NASDAQ:KROS opened at $11.03 on Thursday. The company has a market cap of $218.72 million, a price-to-earnings ratio of -2.98 and a beta of 0.99. The firm’s 50-day simple moving average is $10.78 and its 200-day simple moving average is $11.61. Keros Therapeutics has a fifty-two week low of $9.69 and a fifty-two week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. On average, research analysts forecast that Keros Therapeutics will post -5.27 EPS for the current year.

Insider Transactions at Keros Therapeutics

In other Keros Therapeutics news, Director Nima Farzan sold 2,625 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total value of $28,166.25. Following the sale, the director owned 9,767 shares of the company’s stock, valued at approximately $104,799.91. This represents a 21.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julius Knowles sold 2,625 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the transaction, the director owned 10,958 shares of the company’s stock, valued at approximately $117,579.34. This represents a 19.33% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,768 shares of company stock valued at $144,979 in the last three months. 12.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Keros Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after purchasing an additional 1,166 shares in the last quarter. California State Teachers Retirement System increased its stake in shares of Keros Therapeutics by 72.6% during the 2nd quarter. California State Teachers Retirement System now owns 2,729 shares of the company’s stock worth $29,000 after purchasing an additional 1,148 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Keros Therapeutics by 149.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after purchasing an additional 1,888 shares during the last quarter. Legal & General Group Plc acquired a new position in shares of Keros Therapeutics during the 2nd quarter worth approximately $90,000. Finally, XTX Topco Ltd purchased a new stake in Keros Therapeutics in the 4th quarter valued at approximately $212,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-?) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.